Shionogi & Co., Ltd. (TYO:4507)
Japan
· Delayed Price · Currency is JPY 3,389.00
-62.00 (-1.80%)
At close: Mar 9, 2026
Shionogi & Revenue
Shionogi & had revenue of 147.72B JPY in the quarter ending December 31, 2025, with 23.48% growth. This brings the company's revenue in the last twelve months to 465.38B, up 1.86% year-over-year. In the fiscal year ending March 31, 2025, Shionogi & had annual revenue of 438.27B with 0.73% growth.
Revenue (ttm)
465.38B
Revenue Growth
+1.86%
P/S Ratio
6.20
Revenue / Employee
93.92M
Employees
4,955
Market Cap
2,883.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 438.27B | 3.19B | 0.73% |
| Mar 31, 2024 | 435.08B | 8.40B | 1.97% |
| Mar 31, 2023 | 426.68B | 91.55B | 27.32% |
| Mar 31, 2022 | 335.14B | 37.96B | 12.77% |
| Mar 31, 2021 | 297.18B | -36.19B | -10.86% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Eisai | 808.19B |
| Takeda Pharmaceutical Company | 4,464.58B |
| Sumitomo Pharma | 453.40B |
| Hisamitsu Pharmaceutical Co. | 159.27B |
| Nippon Shinyaku | 166.05B |
| Toho Holdings | 1,539.60B |
| Tsumura & Co. | 189.50B |
| Sawai Group Holdings | 200.68B |
Shionogi & News
- 6 weeks ago - Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits - Reuters
- 1 year ago - Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease - Business Wire